Global Kidney Cancer Drugs Market 2015-2019
About Kidney Cancer
Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders.Kidney cancer can be triggered by a number of factors including both lifestyle-related changes and genetic changes. The surgical removal of affected cancerous cells from the kidney provides a complete cure of the disease. A number of drugs are also available, which also help in the treatment of the disease when it is diagnosed at earlier stages.
Technavio's analysts forecast the global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer.The three regions covered in the report are as follows:
Technavio Announces the Publication of its Research Report – Global Kidney Cancer Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Kidney Cancer Drugs Market: Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis and Pfizer
Other Prominent Vendors in the market are: Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, TRACON Pharmaceuticals and Wilex
Commenting on the report, an analyst from Technavio’s team said: “Individuals tend to develop resistance to monotherapies over a period, resulting in the increased preference for combination therapies, which are safe and more effective in the treatment of kidney cancer. For instance, Avastin (bevacizumab) in combination with interferons slows the proliferation of the disease. Combination drugs are selected depending upon the health condition of the patient and the severity of the disease. Combinations of IL-2 with interferons were more effective than IL-2 or interferon alone. Many other combination therapies are currently under investigation. For example, TRACON Pharmaceuticals is engaged in the phase II development of TRC-105 in combination with Inlyta for the treatment of RCC.”
According to the report, the prevalence of kidney cancer worldwide has increased in recent years. Changes in lifestyle, increased consumption of alcohol, excessive smoking, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Apart from these, the growing elderly population also results in a high incidence of the disease, as kidney cancer usually affects individuals aged 45 and above. In addition, the prevalence of the disease was higher in developed countries than in developing nations. These factors together account for a steady rise in the patient population opting for kidney cancer medication.
Further, the report states that a limited number of approved drugs for the treatment of kidney cancer are present in the market.
Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, TRACON Pharmaceuticals, Wilex
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook